CLAIMS

What is claimed is:

1. A chimeric oncolytic virus, comprising:

a herpesvirus having a modified nucleic acid sequence, comprising:

a modification of the herpesvirus gamma (1)34.5 gene ($\gamma_1$34.5) or a nucleic acid with at least about 70% homology to the $\gamma_1$34.5 gene that reduces its expression;

a second viral nucleic acid sequence encoding a PKR evasion protein is a cytomegalovirus (CMV) nucleic acid and an associated promoter; and

a third nucleic acid sequence encoding a tumor-associated antigen; wherein the tumor-associated antigen includes a secreted protein, a dendritic cell-binding peptide, a glioblastoma-associated antigen, or a full-length EphA2.

2. The chimeric oncolytic virus of claim 1, wherein the herpesvirus is an α herpesvirus.

3. The chimeric oncolytic virus of claim 1, wherein the herpesvirus is an HSV-1 herpesvirus.

4. The chimeric oncolytic virus of claim 1, wherein the modification of the herpesvirus $\gamma_1$34.5 gene comprises a deletion or mutation of the $\gamma_1$34.5 gene.

5. The chimeric oncolytic virus of claim 1, wherein the CMV nucleic acid comprises an IRS-1 gene or a nucleic acid having at least 70% homology to the IRS-1 gene.

6. The chimeric oncolytic virus of claim 1, wherein the tumor-associated antigen includes a dendritic cell-binding peptide.

7. The chimeric oncolytic virus of claim 1, wherein the tumor-associated antigen is a secreted protein.

8. The chimeric oncolytic virus of claim 1, wherein the tumor-associated antigen includes a glioblastoma-associated antigen.

9. The chimeric oncolytic virus of claim 1, wherein the tumor-associated antigen is EphA2.

10. The chimeric oncolytic virus of claim 1, wherein the third nucleic acid sequence is inserted into the chimeric oncolytic virus at the γ134.5 locus.

11. The chimeric oncolytic virus of claim 1, wherein the herpesvirus includes a fourth nucleic acid sequence encoding a different tumor-associated antigen from that encoded by the third nucleic acid sequence.